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1036Objective: Coagulopathy is an important cause of bleeding after complex cardiac surgery. The conventional
treatment for coagulopathy is transfusion, which is associated with adverse outcomes. We report our initial
experience with the prothrombin complex concentrate FEIBA (factor VIII inhibitor bypassing activity) for
the rescue treatment of coagulopathy and life-threatening bleeding after cardiac surgery.
Methods: Twenty-five patients who underwent cardiac surgery with coagulopathy and life-threatening bleeding
refractory to conventional treatment received FEIBA as rescue therapy at our institution. This cohort represents
approximately 2% of patients undergoing cardiac surgery in our university-based practice during the study.
Results: The patients were at high risk for postoperative coagulopathy with nearly all patients having at least 2
risk factors for this. Aortic root replacement (Bentall or valve-sparing procedure) and heart transplant with or
without left ventricular assist device explant were the most common procedures. The mean FEIBA dose was
2154 units. The need for fresh frozen plasma and platelet transfusion decreased significantly after FEIBA
administration (P ¼ .0001 and P< .0001). The mean internationalized normalized ratio decreased from
1.58 to 1.13 (P< .0001). Clinical outcomes were excellent. No patient returned to the operating room for
reexploration. There was no hospital mortality and all patients were discharged home. One patient who had a
central line and transvenous pacemaker developed an upper extremity deep vein thrombosis.
Conclusions: Our initial experience with FEIBA administration for the rescue treatment of postoperative
coagulopathy and life-threatening bleeding has been favorable. Further studies are indicated to confirm its
efficacy and safety and determine specific clinical indications for its use in patients undergoing cardiac surgery.
(J Thorac Cardiovasc Surg 2014;147:1036-40)Coagulopathy is a frequent complication of cardiac surgery
and cardiopulmonary bypass.1 The causes of coagulopathy
are multifactorial, and include excessive fibrinolysis,
platelet dysfunction, and coagulation factor deficiency due
to consumption and dilution,1-4 Especially after complex
operations, coagulopathy is associated with bleeding and
the need for blood component transfusion and surgical
reexploration, all of which have been linked to adverse
outcomes and prolonged length of stay.1,2,5-7 The
mainstays of treatment for coagulopathy associated with
cardiac surgery are antifibrinolytic drug therapy to prevent
excessive fibrinolysis, and blood component transfusion
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The Journal of Thoracic and Cardiovascular SurThese therapies, however, are frequently ineffective and
are themselves associated with adverse outcomes.7-11
Therefore, there is a need for novel therapies that can
effectively and safely treat coagulopathy after cardiac
surgery and prevent the complications associated with it.
Several plasma-derived and recombinant coagulation
factors are available for systemic administration and have
been used for the treatment of coagulopathy after cardiac
surgery. Experience with the use of recombinant factor
VIIa is increasing and its efficacy is being demonstrated,
however this has been associated with thrombotic
risk and has a substantial cost.12-20 Prothrombin complex
concentrates (PCCs) are plasma-derived concentrates of
vitamin Kdependent factors II, VII, IX, and X.21-24 There
has been some experience with the use of PCCs to reverse
warfarin anticoagulation in patients undergoing emergency
cardiac surgery but PCCs have not been studied
systematically for the treatment of coagulopathy after
cardiopulmonary bypass.25-27 In this study, we report our
initial experience with PCCs for the rescue treatment of
coagulopathy and life-threatening bleeding after cardiac
surgery.METHODS
Demographic and perioperative clinical information are collected
prospectively for all patients undergoing cardiac surgery at Oregon Healthgery c March 2014
Abbreviations and Acronyms
FEIBA ¼ factor VIII inhibitor bypassing activity
LVAD ¼ left ventricular assist device
PCC ¼ prothrombin complex concentrates
Song et al Perioperative Management& Science University Hospital. An institutional pharmacy database was
surveyed to identify all patients who underwent cardiac surgery and
received the PCC product factor VIII inhibitor bypass activity (FEIBA;
Baxter Healthcare Corporation; Deerfield, Ill) from July 2011 to October
2012.21 Twenty-five patients were identified and included in this study.
Intraoperative ε-aminocaproic acid was administered to all patients as a
5-g intravenous loading dose and 30 mg/kg/h infusion. An additional 5 g
was included in the cardiopulmonary bypass machine prime. All patients
underwent standard heparinization (300-400 IU/kg) before cardiopulmo-
nary bypass and activated clotting times were maintained at greater than
480 seconds. At the conclusion of cardiopulmonary bypass, heparin was
reversed with protamine sulfate at a dose based on the measured level of
circulating heparin. A cell saver and cardiotomy suction were used in all
cases.
Patients who were treated with therapeutic levels of warfarin at the time
of surgery received fresh frozen plasma (4-6 units) before weaning from
bypass. After heparin reversal, any observed coagulopathy was treated
empirically with standard transfusion of platelets, fresh frozen plasma,
and cryoprecipitate. Transfusion was also guided by point-of-care
thromboelastography, prothrombin and activated partial thromboplastin
times, and platelet count. Packed red blood cells were transfused to main-
tain a hematocrit greater than 21%. If the surgeon noted that coagulopathy
and life-threatening bleeding persisted despite conventional treatment,
FEIBA was administered (1000-4000 units) as a slow intravenous push.
FEIBAwas only administered intraoperatively before chest closure.
Nominal data are presented as frequencies and percentages. Continuous
data are reported with the mean, range, and standard deviation.
Comparisons before and after administration of FEIBA (fresh frozen
plasma and platelet transfusion, internationalized normalized ratio, partial
thromboplastin time, and fibrinogen) were performed with the two-tailed
Student t test.
Institutional review board approval was obtained for this study.
The requirement for individual consent was waived.P
MRESULTS
Twenty-five patients who received FEIBA as rescue
therapy after failing conventional treatment of coagulo-
pathy were identified. This represents approximately 2%
of all patients undergoing cardiac surgery at our institution
during the study period. Demographic and clinical data are
summarized in Table 1. The mean age of the patients was
relatively low for an adult cardiac surgery population
(49.6 years) and reflects the types of surgical procedures
performed. All patients had either an aortic procedure, a
left ventricular assist device (LVAD) implant, or a heart
transplant with or without an LVAD explant. There were
no coronary artery bypass procedures performed in this
group. The preoperative hematologic profile of most
patients was unremarkable, with the exception of the
international normalized ratio. Twelve patients were
anticoagulated with warfarin at the time of their surgery.The Journal of Thoracic and CarIn all instances, these patients had heart failure and required
anticoagulation because of ongoing LVAD support or were
anticoagulated because of their risk or previous history of
left ventricular thrombus. The urgent or emergency nature
of their procedures did not allow time for warfarin to be
stopped before their surgery. Patients with an LVAD
admitted for heart transplantation did receive a dose of
intravenous vitamin K in the hours before their heart
transplant as part of our institutional protocol.
All patients had at least 1 risk factor for the development
of coagulopathy after cardiac surgery, and most had
multiple risk factors (Table 2). Most risk factors were
related to the patient’s clinical condition or planned
procedure and were apparent before the operation. The
most common risk factors for coagulopathy were prolonged
cardiopulmonary bypass time, preoperative anticoagula-
tion, aortic surgery, and redo sternotomy.
All patients had complete reversal of heparinization with
protamine after cessation of cardiopulmonary bypass.
Sufficient protamine was administered so that circulating
heparin levels were undetectable and activated clotting
times were returned to baseline levels. Coagulopathy was
then treated with conventional blood product transfusion.
Blood product transfusion was typically empiric with addi-
tional guidance from point-of-care thromboelastography,
platelet counts, and prothrombin times. If the surgeon noted
that a patient had ongoing coagulopathic bleeding despite
these measures and no clear surgical source could be
identified, FEIBA was administered as a rescue treatment.
The mean FEIBA dose was 2154 units (Table 3). Early in
our experience, we gave FEIBA in 1000-unit increments
to achieve the desired hemostatic effect. Later, we simply
administered 2000 units in a single dose, which was
typically sufficient. Eighteen patients received 2000 units.
Blood product use decreased substantially after FEIBA
administration (Table 3). Patients received a mean fresh
frozen plasma transfusion of 4.76 units before FEIBA and
0.68 units after FEIBA (P ¼ .0001). Platelet transfusion
was reduced from 2.76 units to 0.52 units after FEIBA
administration (P < .0001). Seventeen patients received
no further plasma or platelet transfusion in the postoperative
period after FEIBA administration. Cryoprecipitate was
only given to 2 patients in the series. The mean packed
red blood cell transfusion for patients in the perioperative
period was 1.16 units and 16 patients did not receive red
blood cell transfusion. No recombinant coagulation factors
such as factor VIIa were given to any patients in the series.
Pre- and post-FEIBA dosing coagulation studies were
available for comparison in 17 patients (Table 4). The
international normalized ratio was significantly reduced
in these patients without a notable change in partial
thromboplastin time or fibrinogen levels. Blood loss was
not measured intraoperatively. In the first 3 postoperative
days, the mean chest tube drainage was 664, 549, anddiovascular Surgery c Volume 147, Number 3 1037
TABLE 1. Demographic and preoperative clinical data
Characteristic Value
Patient data
Mean age, y (range) 49.6 (28-72)
Male gender, n (%) 20 (80)
Procedure, n (%)
Urgent status 14 (56)
Emergency status 1 (4)
Redo sternotomy 10 (40)
Bentall procedure 5 (20)
Valve-sparing aortic root replacement 3 (12)
Valve replacement or repair 3 (12)
Ascending aortic replacement 3 (12)
Aortic arch replacement 2 (8)
LVAD explant 6 (24)
LVAD implant 5 (20)
Heart transplant 9 (36)
Preoperative hematologic studies
Mean hemoglobin (g/dL) 13.1
Mean platelet count (31000/mL) 191
Mean international normalized ratio 1.54
LVAD, Left ventricular assist device.
TABLE 3. FEIBA dosing and blood product use
Blood product use Dosing
FEIBA
Mean FEIBA dose (units) 2154 (range, 1000-4000; SD, 781)
Transfusion
Mean FFP transfusion before
FEIBA (units)
4.76 (range, 2-10; SD, 2.5)
Mean FFP transfusion after
FEIBA (units)
0.68 (range, 0-7; SD, 1.5; P ¼ .0001)
Mean platelet transfusion
before FEIBA (units)
2.76 (range, 1-5; SD, 1.0)
Mean platelet transfusion after
FEIBA (units)
0.52 (range, 0-5; SD, 1.1; P<.0001)
FEIBA, Factor VIII inhibitor bypassing activity; FFP, fresh frozen plasma; SD, stan-
dard deviation.
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M331 mL (Table 5), which is similar to what is observed in
our patients who do not develop coagulopathy.
The clinical outcomes in this series of complex patients
were excellent. All patients had their chests closed
primarily without packing. No patients were returned to
the operating room for reexploration for bleeding. There
was no operative (30-day) mortality. The mean intensive
care unit stay was 7 days and the mean total hospital length
of stay was 12.8 days. All patients were discharged to home.
One patient who had transvenous implantable cardioverter
defibrillator leads before heart transplantation and a central
line placed at the time of surgery developed an upper
extremity deep vein thrombosis. There were no other
thrombotic complications.TABLE 2. Preoperative risk factors for coagulopathy and bleeding
Risk factor Number (%)
Marfan syndrome 4 (16)
Preoperative anticoagulation 12 (48)
Redo sternotomy 10 (40)
Heart transplant 9 (36)
Aortic surgery 11 (44)
LVAD explant 6 (24)
LVAD implant 5 (20)
Cardiopulmonary bypass>180 min 14 (56)
Circulatory arrest 2 (8)
Number of risk factors
1 risk factor 2 (8)
2 risk factors 7 (28)
3 risk factors 10 (40)
4 or more risk factors 6 (24)
LVAD, Left ventricular assist device.
1038 The Journal of Thoracic and Cardiovascular SurCONCLUSIONS
Coagulopathy is an important risk factor for bleeding and
transfusion and is associated with both early and late
morbidity in patients undergoing cardiac surgery.1,2,5,6
This study describes our early experience with FEIBA, a
novel treatment for coagulopathy in patients undergoing
cardiac surgery who have failed conventional treatment
for this. Our experience has been favorable, with dramatic
improvement in coagulation, reduction in transfusion
requirements, and avoidance of reexploration for ongoing
bleeding. The safety profile of the treatment has also been
reassuring, with a thrombotic complication occurring in
only 1 patient who had other risk factors predisposing
him to this.
FEIBA is composed of factors II, IX, and X, which are
mostly nonactivated, and small amounts of factor VIIa.21
It acts on steps in the intrinsic and extrinsic coagulation
pathways to facilitate thrombin generation on the platelet
surface.28 Given the common use of recombinant factor
VIIa for similar indications in patients undergoing cardiac
surgery, our positive experience with FEIBA, which
contains factor VIIa, is perhaps unsurprising. We chose to
use the FEIBA PCC preparation because it contains factor
VIIa, unlike other PCC preparations available in the United
States. Recombinant factor VIIa administration has been
associated with a significant incidence of thrombotic
complications, however.16 FEIBA may have an advantage
in this regard because it contains multiple coagulation
factors and acts on both coagulation pathways, possibly
leading to a reduced dosing requirement compared with
the pharmacologic levels achieved with factor VIIa treat-
ment. The typical dose used in our series was approximately
20 units/kg which is only 20%-50% of that used for its
approved indication in hemophiliacs with inhibitors.29 We
have also observed that the effect of FEIBA administration
on the international normalized ratio was less dramatic than
that typically seen with recombinant factor VIIa even
though the clinical hemostatic effect in our experience hasgery c March 2014
TABLE 4. Pre- and post-FEIBA coagulation profiles
International normalized ratio Partial thromboplastin time (seconds) Fibrinogen (mg/L)
Pre-FEIBA Post-FEIBA Pre-FEIBA Post-FEIBA Pre-FEIBA Post-FEIBA
1.58 (range, 1.12-2.29;
SD, 0.24)
1.13 (range, 0.92-1.43;
SD, 0.15; P<.0001)
36.11 (range, 29.3-64.3;
SD, 8.8)
35.36 (range, 28.6-55.3;
SD, 7.5; P ¼ .8)
272.9 (range, 130-377;
SD, 74)
263.8 (range, 167-396;
SD, 69; P ¼ .51)
FEIBA, Factor VIII inhibitor bypassing activity; SD, standard deviation.
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center was also substantially lower than that associated
with the use of recombinant factor VIIa.30
Procoagulants such as FEIBA and recombinant factor
VIIa are not approved for patients undergoing cardiac
surgery in the United States. For this reason, we have
used FEIBA cautiously, as a rescue treatment only in a
small subpopulation of our patients who had ongoing
coagulopathy and bleeding despite conventional transfusion
treatment. This determination was made by the surgeon in
the operating room before chest closure, so that the
coagulopathy and the response to treatment could be
directly observed. We believe this is the safest setting to
administer procoagulants to avoid overuse and thrombotic
complications. This policy has led to a change in our
practice in that the transfusion and resuscitation phase of
care of these complex cases is initiated and completed in
the operating room. Patients do not leave the operating
room with ongoing coagulopathy but have this addressed
completely before chest closure. We believe this practice
contributed to the excellent outcomes observed: all patients
had their chest closed without packing, no patients required
reexploration, and red blood cell transfusion was avoided
altogether in 16 patients.
Most patients in this study had multiple risk factors
for coagulopathy. Potentially, these patients could be
prospectively identified as being at high risk for requiring
procoagulants such as FEIBA or recombinant factor VIIa
to stop bleeding. As our experience with procoagulants
increases, we may be able to prophylactically treat certain
categories of high-risk patients, such as those undergoing
aortic dissection repair under circulatory arrest, to avoid
or limit transfusion rather than using procoagulants solely
as a rescue therapy.31 In the future, this may be the most
efficient way to minimize transfusion and its deleterious
effects on patients undergoing complex cardiac procedures.
This study does have several limitations. It is a retro-
spective study of a relatively small number of patients.
Patients were relatively young and no patients hadTABLE 5. Postoperative chest tube drainage volume
Postoperative day
Chest tube drainage volume (mL)
Mean Range Standard deviation
1 664 145-1985 430
2 549 170-1260 339
3 331 100-1040 222
The Journal of Thoracic and Carcoronary artery bypass grafting. Their risk for thrombotic
complications was therefore likely lower than that of a
typical cardiac surgery population. Different PCCs on the
market contain coagulation factors in varying amounts
and our experience may not necessarily be generalized to
all PCC formulations. In addition, we did not collect cost
data, and therefore were unable to provide an economic
analysis of this treatment strategy. Despite these limitations,
our early experience suggests that this approach holds
promise for the treatment of coagulopathy in some
populations of patients undergoing cardiac surgery. Further
study of procoagulants in patients undergoing cardiac
surgery is warranted.References
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